• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

CNS Therapeutics - Global Strategic Business Report

  • ID: 516891
  • February 2015
  • Region: Global
  • 482 Pages
  • Global Industry Analysts, Inc

This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as :

- AbbVie Inc.
- Actavis Plc
- Alkermes Plc
- Amneal Pharmaceuticals, LLC
- Aspen Pharmacare Holdings Limited

Note: Product cover images may vary from those shown

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Anti-Alzheimer's Drugs
Anti-Parkinson's Drugs
Anti-Epilepsy Drugs
Pain Management Drugs
Anti-Psychotics Drugs
Bipolar disorder
Schizophrenia
Anti-Depressants Drugs
Others
Attention Deficit Hyperactivity Disorder
Multiple Sclerosis
Insomnia

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW
CNS Therapeutics Exhibit Robust Opportunities amidst Rising Incidence of CNS Disorders
Patent Expiries of Major Drugs Exert Downward Pressure on the Global CNS Market
Patent Expiries of Leading CNS Drugs: 2008-2022
Aging Demographics and Improved Diagnosis Drive Market Growth
Table 1: Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)
Table 2: Percentage Share Breakdown of Global Population by Age Group, Worldwide: 2025 (includes corresponding Graph/Chart)
Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
Key Statistical Data:
Table 3: Global Spending on Prescription Drugs by Country (2014): Percentage Share Breakdown of Dollar Spending (includes corresponding Graph/Chart)
Table 4: Per Capita Healthcare Expenditure in US$ by Select Country (includes corresponding Graph/Chart)
Table 5: Healthcare Expenditure as % of GDP by Select Country (includes corresponding Graph/Chart)
Developed Markets to Maintain their Dominance
Developing Market to Drive the Market Momentum

2. NOTEWORTHY MARKET TRENDS, GROWTH DRIVERS & ISSUES
Growing Penetration of Generic Drugs Emerges as a Key Trait
Table 6: Global Spending on Generic Drugs Vis-à-vis Branded Drugs (2013 & 2018): Percentage Share Breakdown of Dollar Spending by Drug Category (includes corresponding Graph/Chart)
Table 7: Spending on Prescription Medicines in Developed Economies (2013 & 2018): Percentage Share Breakdown of Dollar Spending by Drug Category (includes corresponding Graph/Chart)
Table 8: Spending on Prescription Medicines in Developing Economies (2013 & 2018): Percentage Share Breakdown of Dollar Spending by Drug Category (includes corresponding Graph/Chart)
Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
Branded Generic CNS Drugs: A Key Revenue Spinner in Emerging Countries
Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
Awareness Campaigns Launched by Pharma Companies to Benefit the Market
China’s Growing Role to Help Global CNS Therapeutics Market Make Significant Gains
Select Available and Pipeline CNS Drugs in China
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China
Select Pipeline CNS Drugs in China
Key Challenges
Healthcare Cost Rationing & Government Caps Challenge Branded CNS Drugs
Drug Trial Failures Continue to Hamper Neuroscience Research & the Overall Market Prospects

3. MARKET ANALYSIS BY THERAPEUTIC CATEGORIES
Anti-Epilepsy Market
Market Overview
Table 9: Epilepsy Incidence by Type (2014): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy (includes corresponding Graph/Chart)
Table 10: Symptomatic Epilepsy Incidence by Type (2014): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy (includes corresponding Graph/Chart)
Treatment
Anti-Epileptic Market (AEDs) by Drug Class: List of Drugs under Broad-Spectrum AEDs and Narrow-Spectrum AEDs
Leading Anti-Epileptic Drugs
Leading Anti-Epileptic Drugs and Their Mechanism of Action
Patent Expiries of Major Anti- Epilepsy Drugs
High Unmet Needs Offer Scope for Market Growth
Select Currently Available Epilepsy Drugs
Select Anti-Epilepsy Drugs (AEDs) in Phase III Trials
Innovative Drugs Needed for Better Treatment Compliance
Abounding Potential for NCEs
Developed Countries Account for a Major Share of Epilepsy Treatment
Table 11: The US Epilepsy Market by Drug Category (2014): Percentage Market Share Breakdown of Total Prescriptions for Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Topiramate, and Others (includes corresponding Graph/Chart)
Developing Countries Struggle with Low Treatment Rates
Refractory Childhood Epilepsy & Pregnancy Epilepsy
Major Concerns
Review of Anti-Epilepsy Drugs
Vimpat®
Keppra®
Lamictal
Tegretol®
Sabril®
Perampanel
Zonegran®
Topamax®
Trileptal®
Neurontin®
Lyrica®
Depakine®
CNS Pain Management
Market Overview
Drugs Indicated for Pain Management
Combination Therapies Gain Prominence
Neuropathic Pain Management: Market with High Potential
Migraine Market: A Core Vertical in CNS Pain Management
Migraine Care: Select Patent Expiries (2013-2015)
Select Pain Management Drugs
Flupirtine
Lyrica®
Oxycodone
Nucynta ER
Metabotropic Glutamate Receptors (mGluRs)
Anti-Alzheimer's
Market Overview
Table 12: Alzheimer's Prevalence by Age Group (includes corresponding Graph/Chart)
Treatment for Alzheimer’s
Select Leading Drugs for Alzheimer's Disease by Drug Category
Patent Expiries of Leading Alzheimer’s Drugs
Table 13: Alzheimer’s Leading Drug Sales (in US$ Million): 2012 (includes corresponding Graph/Chart)
Promising Pipeline Drugs to Elevate Future AD Treatment
Pipeline Drugs for Alzheimer’s Disease
A Review of Select Anti-Alzheimer’s Drugs
Aricept
Exelon
Reminyl
Ebixa
Namenda
Anti-Parkinson's
Market Overview
Levodopa
The “Gold Standard” for Parkinson’s Treatment
Table 14: Global Anti-Parkinson's Drugs Market by Leading Drugs (2014): Percentage Share Breakdown for Revenues by Drug Category (includes corresponding Graph/Chart)
Table 15: Percentage Share Breakdown of Revenues for Levodopa Franchise in the US: 2013 (includes corresponding Graph/Chart)
Pipeline Drugs for Parkinson's Diseases: As on August, 2013
Select Anti-Parkinson’s Drugs
Levodopa
Dopamine Agonists
Mirapex
Requip
Anti-Depressants
Market Overview
Pipeline Anti-Depressant Drugs
Select Antidepressants Drugs
Zoloft (Sertraline)
Cymbalta®
Prozac (Fluoxetine)
Effexor (Venlafaxine)
Paxil
Wellbutrin (Bupropion)
Anti-Psychotics
Market Overview
Table 16: Global Antipsychotics Market by Leading Brand (2014): Percentage Market Share Breakdown of Revenues for Abilify, Geodon, Invega, Invega Sustenna, Risperdal, Risperdal Consta, Seroquel, Zyprexa, and Others (includes corresponding Graph/Chart)
Prevalence of Schizophrenia and Bipolar Disorders: Statistical Snippets
Second Generation Antipsychotics Beset with Safety Issues
Companies Focus on Next Generation Products to Deflect the Heat of Competition
Pipeline Drugs for Schizophrenia & Bipolar disorders
Select Anti-Psychotic Drugs
Zyprexa
Seroquel
Abilify
Clozaril
Risperdal
Risperdal® Consta®
Geodon
Invega Sustenna
Saphris
Latuda
Other CNS Disorders
Attention Deficit Hyperactivity Disorder (ADHD)
Market Overview
Pipeline Drugs for ADHD
Select ADHD Drugs
Concerta
Strattera
Adderall
Multiple Sclerosis (MS)
Table 17: Global Multiple Sclerosis Market by Leading Brand (2014): Percentage Market Share Breakdown of Revenues for Copaxone, Avonex, Tysabri, Tecfidera, Gilenya, Betaseron, Rebif, Aubagio, and Others (includes corresponding Graph/Chart)
Multiple Sclerosis Approved Therapies (Injec
Tables)
Multiple Sclerosis Approved Therapies (Oral)
Efficacy of Injec
Table MS Drugs
Efficacy of Oral MS Drugs
Patent Expiration Date/Year of the Major MS Drugs
Tecfidera to Further Strengthen Biogen’s Leadership
Increased Focus on Reducing the Frequency of Administration
Route & Dosing Frequency of Injec
Table Multiple Sclerosis Products
MS Pipeline
Table 18: Multiple Sclerosis Market: Drugs under Development (includes corresponding Graph/Chart)
Select Pipeline MS Drugs
Established Players Witness Decline in Sales
Insomnia
Overview
Select Pipeline Insomnia Drugs
Zolpidem
Eszopiclone
Other Noteworthy CNS Pipeline Drugs

4. PRODUCT OVERVIEW
Definition
Central Nervous System
Mortality Threat of CNS Disorders
Science of NMDA Receptors and its Disease Significance
Major CNS Disorders:
Alzheimer’s Disease
Alzheimer’s Affect on Brain
Causes for Alzheimer’s
Who Are at Risk?
Prevalence of Alzheimer’s Disease
Diagnosis of Alzheimer’s
Parkinson’s Disease
Prevalence
Symptoms
Causes
Diagnosis
Epilepsy
Symptoms of Epilepsy
Types of Epilepsy and Epileptic Seizures
Preventive Measures
Treatment Options for Epilepsy Patients
Treatment Options Available for Epilepsy Patients
Epilepsy Drug Treatment Paradigm
Pain Management
Debilitating Effects of Pain
Types of Pain
Acute Pain
Chronic Pain
Migraine
Neuropathic Pain
Nociceptive Pain
Anti-Psychotics
Bipolar Disorder
Symptoms of Bipolar Disorder
Mood Episode
A Major Symptom
Manic Episode Vs Depressive Episode
Causes of Bipolar Disorder
Types of Bipolar Disorder
Co-morbidities of Bipolar Disorder
Schizophrenia
Prevalence by Gender
Symptoms of Schizophrenia
Causes of Schizophrenia
Therapies for Bipolar Disorder & Schizophrenia
Mood Stabilizing Agents
Antidepressants
Antipsychotic Drugs
Indications of Antipsychotics
An Effective Adjunctive Therapy
Off-label Uses
Efficacy
Marred by Lack of Evidence Base
Types of Antipsychotics
Difference between Typical and Atypical
Atypical Antipsychotics Up Against Typicals
Side Effects of Antipsychotics
Symptoms of Antipsychotics Withdrawal
Controversies Surrounding Antipsychotics
Prohibited Practices
Antipsychotics in Pregnant Women
Depression
Prevalence of Depression
Causes of Depression
Types of Depressive Disorders
Available Treatment
Tricyclic Antidepressants
Monoamine Oxidase Inhibitors
Lithium Salts
Working of Antidepressants
Ranking of Antidepressants in Terms of Efficacy
Types of Antidepressants
NMDA Receptor Antagonists
NMDA Receptor (NMDAR)
NMDA Receptor Agonists
Acetylcholinesterase Inhibitors
Selective Serotonin Reuptake Inhibitors (SSRIs)
Workings of SSRIs
Safety Levels of SSRI Drugs
Adverse Effects of SSRI
Serotonin Noradrenaline Reuptake Inhibitors (SNRIs)
Others Common CNS Disorders
Attention Deficit Hyperactivity Disorder
Consequences of ADHD
What Leads to ADHD?
Treating ADHD
Multiple Sclerosis (MS)
Types of Multiple Sclerosis
Table 19: Clinical Subtypes of Multiple Sclerosis (MS) (includes corresponding Graph/Chart)
Prevalence of MS
Causes of MS
Myths Surrounding Multiple Sclerosis
Symptoms of MS
Diagnosis of MS
Treatment
Insomnia
Prevalence of Insomnia
Therapies for Insomnia

5. PRODUCT INTRODUCTIONS/INNOVATIONS & R&D BREAKTHROUGHS
Eisai Unveils AMPA Receptor Antagonist Fycompa (Perampanel)
Watson Pharmaceuticals Rolls Out REPREXAIN™ CIII
INSYS Therapeutics Launches SUBSYS™ for BTCP Treatment
Omron Healthcare Unveils Omron electroTHERAPY Pain Relief Unit
Sun Pharma, Lupin and Dr Reddy's Introduce Generic Schizophrenia Drug
Mylan Launches Levetiracetam in Sodium Chloride Injection
Dr. Reddy’s Laboratories Introduces Geodon
Sun Pharmaceutical Unveils Zyprexa Zydis
H Lundbeck Introduces Onfi Anti-Epileptic Drug in US
Eisai and Nobelpharma to Introduce Fostoin Anticonvulsant Agent
Eisai Europe Launches Zebinix® Eslicarbazepine Acetate
Eisai Launches Fycompa
H. Lundbeck Introduces Sycrest
GW Pharmaceuticals to Develop Cannabis-Based Epileptic Treatment
Teva Pharmaceutical Industries Introduces Quetiapine and Quetiapine XL
Eisai to Unveil Zonegran Drug Treatment in Russia

6. RECENT INDUSTRY ACTIVITY
Actavis Takes Over Forest Laboratories
Teva Pharmaceutical Snaps Up Labrys
Teva Pharmaceutical Acquires NuPathe
Alkermes Announces New Developments for ALKS 5461 and Aripiprazole Lauroxil
Allergan Receives FDA Rejection for Semprana
Mallinckrodt Receives FDA Approval for PENNSAID 2% Formulation
Takeda Pharmaceutical to Redesign its Global Organizational Structure
Boehringer Ingelheim Teams Up with Hydra Biosciences
BIAL Signs Exclusive Licensing Agreement with moksha8
Actavis and Adamas Pharmaceuticals Receive USFDA Approval for NDA for Namzaric
IntelGenx and RedHill Biopharma Receive USFDA’s CRL for VersaFilm™ Oral Film Product
Alkermes Achieves Positive Phase I Results for ALKS 3831
Teva Pharmaceutical Industries to Disclose Study Results for AZILECT® Rasagiline
Tablets
Johnson & Johnson Pays Fine for Illegal Marketing
Perrigo Takes Ove Elan
Lundbeck Expands Collaboration with Otsuka
Eisai Receives Finnish Approval for Fycompa
Sunovion Files two sNDAs for Latuda®
Mylan Pharmaceuticals Receives FDA Approval for Lithium Carbonate Extended-release
Tablets USP
Supernus Obtains Approval for Oxtellar XR Anti-Epilepsy Drug
FDA Delays the Launch of Antipsychotic Drug by Otsuka and Lundbeck
Forest Laboratories Submits NDA for Cariprazine
GSK Agrees to Pay Criminal Fine for Illegal Promotion
Novartis Discontinues Development of Fanapt
Qualitest Pharmaceuticals Obtains FDA Approval for Levetiracetam
Tablets
Prasco Laboratories Inks Agreement with Shire
Par Pharmaceutical and Handa Pharmaceuticals Ink Licensing Agreement
Zogenix Inks Exclusive Co-Promotion Agreement with Mallinckrodt
Actavis Signs Agreement with QrxPharma to Market MOXDUO® IR
Mallinckrodt Receives FDA Approval for EXALGO®
Tablet
Pfizer Receives FDA Approval for Lyrica® Capsules
Sunovion Files for Expanded Use of Latuda®
Glenmark Generics Obtains FDA Approval for Lamotrigine
Mylan Obtains FDA Approval for Levetiracetam Extended-Release
Tablets
Mallinckrodt Acquires CNS Therapeutics
Neurodyn Takes Over NeuroQuest
Paladin Labs and QRxPharma Sign Licensing Agreement
Sanofi and Alfresa Pharma Ink Agreement to Develop Vigabatrin
Otsuka Files for Additional Indication for Abilify®
UCB and Otsuka Pharmaceuticals to Develop Anti-Epileptic Drugs
Eisai Receives Manufacturing License in the UK
Dainippon Sumitomo and Takeda Receive Acceptance from the EMA
Dainippon Sumitomo Inks an Agreement with Takeda
Aspen Global to Take Over Drug Portfolio of GlaxoSmithKline
Upsher-Smith Laboratories Takes Over Proximagen Group
Eisai Receives Approval for Fycompa Drug
UCB Discloses Epilepsy Drug Trial Results
Eisai Europe Obtains Approval for Zonegran® Anti-Epileptic Agent
Forest Laboratories Enters into Broad Strategic Alliance with moksha8
Moksha8 Extends License Agreement with Watson Pharmaceuticals

7. FOCUS ON SELECT GLOBAL PLAYERS
AbbVie Inc. (USA)
Actavis Plc. (Ireland)
Alkermes Plc. (Ireland)
Amneal Pharmaceuticals, LLC (USA)
Aspen Pharmacare Holdings Limited (Australia)
AstraZeneca Plc (UK)
BIAL Group (Portugal)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb (USA)
Dainippon Sumitomo Pharma Co., Ltd. (Japan)
Eisai Co., Ltd. (Japan)
Eli Lilly and Co. (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Fabre-Kramer Pharmaceuticals, Inc. (USA)
GlaxoSmithKline (UK)
H. Lundbeck A/S (Denmark)
Johnson & Johnson (USA)
Janssen Pharmaceuticals, Inc. (USA)
Merck & Co., Inc. (USA)
Neurocrine Biosciences, Inc. (USA)
Novartis AG (Switzerland)
Otsuka Pharmaceutical Co., Ltd. (Japan)
Pfizer, Inc. (USA)
Sanofi S.A (France)
Shire Plc (UK)
Sunovion Pharmaceuticals, Inc. (USA)
Takeda Pharmaceutical Co., Ltd. (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
UCB Group (Belgium)

8. GLOBAL MARKET PERSPECTIVE
Table 20: World Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 21: World Historic Review for CNS Therapeutics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 22: World 14-Year Perspective for CNS Therapeutics by Geographic Region
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 23: World Recent Past, Current & Future Analysis for Anti-Alzheimer’s by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 24: World Historic Review for Anti-Alzheimer’s by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 25: World 14-Year Perspective for Anti-Alzheimer’s by Geographic Region
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 26: World Recent Past, Current & Future Analysis for Anti-Parkinson’s by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 27: World Historic Review for Anti-Parkinson’s by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 28: World 14-Year Perspective for Anti-Parkinson’s by Geographic Region
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 29: World Recent Past, Current & Future Analysis for Anti-Epilepsy by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 30: World Historic Review for Anti-Epilepsy by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 31: World 14-Year Perspective for Anti-Epilepsy by Geographic Region
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 32: World Recent Past, Current & Future Analysis for Pain Management by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 33: World Historic Review for Pain Management by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 34: World 14-Year Perspective for Pain Management by Geographic Region
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 35: World Recent Past, Current & Future Analysis for Anti-Psychotics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 36: World Historic Review for Anti-Psychotics by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 37: World 14-Year Perspective for Anti-Psychotics by Geographic Region
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 38: World Recent Past, Current & Future Analysis for Anti-Depressants by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 39: World Historic Review for Anti-Depressants by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 40: World 14-Year Perspective for Anti-Depressants by Geographic Region
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 41: World Recent Past, Current & Future Analysis for Others by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 42: World Historic Review for Others by Geographic Region
US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 43: World 14-Year Perspective for Others by Geographic Region
Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES
A.Market Analysis
The Largest CNS Therapeutics Market Globally
Aging Population: A Strong Demographic Driver
Table 44: North American Elderly Population by Age Group (1975-2050) (includes corresponding Graph/Chart)
Table 45: The US Population Breakdown by Age Group (2014) (includes corresponding Graph/Chart)
Patent Expiries Curtail Market Growth
Patent Expiries of Leading CNS Drugs in the US
Focus on Select Markets
Alzheimer’s Market
NAPA Grants Help AD Research
Anti-Epilepsy Market
Epilepsy
A Major Concern for the Healthcare Industry
A Glance at Epilepsy Statistics
Anti-Epilepsy Drugs
Table 46: The US Epilepsy Drugs Market by Type (2014): Percentage Market Share Breakdown of Sales for Levetiracetam, Lamotrigine, Topiramate, Gabapentin, Pregabalin, and Others (includes corresponding Graph/Chart)
Table 47: The US Epilepsy Drugs Market by Leading Brand (2012 & 2018): Percentage Market Share Breakdown of Total Prescriptions for Dilantin, Neurontin, Depakote; and Other Seizure Therapeutics (includes corresponding Graph/Chart)
The US Epilepsy Market: Patent Expiry of Select Major Drugs
Epilepsy in Children
Growing Competition from Generics
Pain Management Market
Table 48: The US Pain Management Market by Leading Player (2014): Percentage Market Share Breakdown of Revenues for Endo, Purdue, Johnson and Johnson Co., Pfizer, Teva, and Others (includes corresponding Graph/Chart)
Neuropathic Pain Market
Anti-Psychotic Drugs Market
Mental Illnesses
Epidemiology
Facts & Figures
Table 49: Lifetime Prevalence (%) of Bipolar Disorder in the US Population by Age Group (includes corresponding Graph/Chart)
Popular Antipsychotic Drugs in the US
Anti-Psychotic Drugs by FDA Approved Age and Indication in the US
Table 50: The US Anti-Psychotic Drugs Market (2014): Percentage Share Breakdown of Value Sales by Indication (includes corresponding Graph/Chart)
Table 51: The US Antipsychotics Market (2014): Percentage Share Breakdown of Prescriptions by Indication (includes corresponding Graph/Chart)
Table 52: The US Atypical Antipsychotic Market by Leading Brand (2014): Percentage Market Share Breakdown of Revenues for Abilify, Invega, Invega Sustenna, Risperdal Consta, Seroquel, Zyprexa, and Others (includes corresponding Graph/Chart)
Table 53: The US Antipsychotic Long-Acting Injec
Tables Market by Leading Drugs (2014): Percentage Market Share Breakdown of Total Prescriptions for Risperdal Consta, Invega Sustenna, Abilify Maintena, and Others (includes corresponding Graph/Chart)
Growth Dampeners
Surging Off-label Prescriptions
Advertising for Antipsychotics Acquires a Whole New Dimension
Illegal Marketing
A Cause of Concern for Governments
Generics Occupy Front Seat
Initiatives by Regulatory Bodies Favor Generics
Initiatives to Cut Spending on Antipsychotics
Antipsychotics Use in Nursing Homes Raises Concern
Rising Antipsychotic Use among Children
A Cause of Concern
ADHD Market
Select Available ADHD Drugs in the US
Table 54: The US ADHD Drugs Market by Leading Brands (2014): Percentage Share Breakdown of Total Prescription Sales for Adderall XR, Intuniv, Vyvanse, and Others (includes corresponding Graph/Chart)
Table 55: The US Non-Stimulant ADHD Market by Leading Brand (2014): Percentage Share Breakdown of Prescription Sales for Intuniv, Strattera, and Others (includes corresponding Graph/Chart)
Table 56: The US ADHD Drugs Market by Drug Category (2014): Percentage Share Breakdown of Total Prescription Sales for Stimulants (Amphetamines and Methylphenidates) and Non-Stimulants (includes corresponding Graph/Chart)
Table 57: The US ADHD Drugs Market by Type (2014): Percentage Share Breakdown of Total Prescription Sales for Branded & Generic Drug Groups (includes corresponding Graph/Chart)
Adult ADHD Drugs Continue to Widen their Share
Table 58: The US ADHD Drugs Market by Drug Category (2014): Percentage Share Breakdown of Total Prescriptions for Adult & Pediatric Patient Groups (includes corresponding Graph/Chart)
Product Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 59: The US Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 60: The US Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 61: The US 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

2. CANADA
A.Market Analysis
CNS Diseases: Facts & Figures
Strategic Corporate Developments
B.Market Analytics
Table 62: Canadian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 63: Canadian Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 64: Canadian 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

3. JAPAN
A.Market Analysis
Graying Population Spurs Growth of CNS Therapeutics
Table 65: Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)
Product Launch
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 66: Japanese Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 67: Japanese Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 68: Japanese 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4. EUROPE
A.Market Analysis
Ageing Population Boosts Demand
Table 69: European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)
European Patent Expiries of Select CNS Drugs
Pain Management Market
Neuropathic Pain Market Witnesses Foray of Generics
Anti-Psychotics Market
Demand for Antipsychotics for Bipolar Disorder Upbeat
Generics to Witness Growth in Bipolar Disorder Therapeutics Market
B.Market Analytics
Table 70: European Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 71: European Historic Review for CNS Therapeutics by Geographic Region
France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 72: European Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 73: European Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 74: European 14-Year Perspective for CNS Therapeutics by Geographic Region
Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 75: European 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4a. FRANCE
A.Market Analysis
Product Launch
Sanofi S.A
A Key French Player
B.Market Analytics
Table 76: French Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 77: French Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 78: French 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4b. GERMANY
A.Market Analysis
Strategic Corporate Development
Boehringer Ingelheim GmbH
A Key German Player
B.Market Analytics
Table 79: German Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 80: German Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 81: German 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4c. ITALY
A.Market Analysis
Market Snapshots
B.Market Analytics
Table 82: Italian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 83: Italian Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 84: Italian 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM
A.Market Analysis
Nice Recommendations on CNS Therapeutics
Product Launches
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 85: The UK Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 86: The UK Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 87: The UK 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4e. SPAIN
Market Analysis
Table 88: Spanish Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 89: Spanish Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 90: Spanish 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4f. RUSSIA
Market Analysis
Table 91: Russian Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 92: Russian Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 93: Russian 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

4g. REST OF EUROPE
A.Market Analysis
Product Launch
Strategic Corporate Developments
Select Key Players
B.Market Analytics
Table 94: Rest of European Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 95: Rest of European Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 96: Rest of European 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC
A.Market Analysis
India & China Offer Significant Growth Opportunities
Table 97: China and India Lead Global Population (July 2013):
Table Depicting China and India’s Huge Population Vis-a-vis Other Countries’ Population (in Million) by Age Group (includes corresponding Graph/Chart)
Growing Antipsychotics Market in Asia
China: The Primary Market for CNS Drugs in Asia-Pacific
Select Anti-Schizophrenia Drugs Available in China
Other Available CNS Drugs in China
Select Pipeline CNS Drugs in China
Strategic Corporate Development
Aspen Pharmacare Holdings Limited
A Key Australian Company
B.Market Analytics
Table 98: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region
China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 99: Asia-Pacific Historic Review for CNS Therapeutics by Geographic Region
China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 100: Asia-Pacific Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 101: Asia-Pacific Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 102: Asia-Pacific 14-Year Perspective for CNS Therapeutics by Geographic Region
Percentage Breakdown of Value Sales for China, India and Rest of Asia-Pacific Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 103: Asia-Pacific 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA
A.Market Analysis
Strategic Corporate Developments
B.Market Analytics
Table 104: Latin American Recent Past, Current & Future Analysis for CNS Therapeutics by Geographic Region
Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 105: Latin American Historic Review for CNS Therapeutics by Geographic Region
Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 106: Latin American Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 107: Latin American Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 108: Latin American 14-Year Perspective for CNS Therapeutics by Geographic Region
Percentage Breakdown of Value Sales for Brazil and Rest of Latin America Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)
Table 109: Latin American 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD
A.Market Analysis
Teva Pharmaceutical Industries Ltd.
A Key Israeli Company
B.Market Analytics
Table 110: Rest of World Recent Past, Current & Future Analysis for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2014 through 2020 (includes corresponding Graph/Chart)
Table 111: Rest of World Historic Review for CNS Therapeutics by Product Segment
Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2013 (includes corresponding Graph/Chart)
Table 112: Rest of World 14-Year Perspective for CNS Therapeutics by Product Segment
Percentage Breakdown of Dollar Sales for Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Other Markets for Years 2007, 2015 & 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 145 (including Divisions/Subsidiaries - 172)
The United States (69)
Canada (11)
Japan (14)
Europe (47)
- France (4)
- Germany (9)
- The United Kingdom (11)
- Italy (1)
- Rest of Europe (22)
Asia-Pacific (Excluding Japan) (23)
Middle East (7)
Africa (1)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Shire PLC. GlaxoSmithKline PLC Astrazeneca PLC Roche Diagnostics Ltd. H. Lundbeck A/S Electrical Geodesics, Inc.